|
Variables
|
n = 100
|
|---|
|
Age (y)
|
58 (48–68)
|
|
Gender, n (% female)
|
82 (82.0%)
|
|
Disease duration (mo)
|
29 (8–84)
|
|
Stage (I/II/III/IV %)
|
40/48/6/6
|
|
Treatment history
|
|
MTX use at baseline, n (%)
|
100 (100%)
|
|
Dose, mg/w
|
14 (10–16)
|
|
Glucocorticoid use at baseline, n (%)
|
8 (8%)
|
|
Dose, mg/day
|
4.5 (2.0–7.0)
|
|
bDMARDS naïve, n (%)
|
73 (73%)
|
|
Prior use of TNFi
|
18 (18%)
|
|
Prior use of Non-TNFi
|
6 (6%)
|
|
Prior use of both TNFi and non-TNFi
|
3 (3%)
|
|
28-tender joint count
|
8 (4–13)
|
|
28-swollen joint count
|
7 (3–11)
|
|
GH, VAS 0-100 mm
|
48 (26–70)
|
|
EGA, VAS 0-100 mm
|
40 (28–60)
|
|
Pain, VAS 0-100 mm
|
52 (28–72)
|
|
DAS28-ESR
|
5.4 ± 1.3
|
|
HAQ-DI
|
1 (0.5–1.5)
|
|
EQ-5D
|
0.6 (0.5–0.7)
|
|
CRP (mg/dl)
|
0.6 (0.1–2.1)
|
|
ESR (mm/h)
|
37 (21–68)
|
|
Rheumatoid factor (U/ml)
|
56.4 (21.1–129.1)
|
|
Anti-CCP antibody (U/ml)
|
95.0 (24.7–384.5)
|
|
MMP-3 (ng/ml)
|
87.3 (34.5–328)
|
- Data are mean ± SD, median (IQR), or number (%) of patients
- MTX methotrexate, bDMARDS biological disease-modifying anti-rheumatic drugs, TNFi TNFα inhibitor, GH VAS patient’s global assessment of disease activity visual analog scale, EGA VAS evaluator global assessment of disease activity visual analog scale, DAS disease activity score, HAQ-DI health assessment questionnaire disability index, EQ-5D EuroQol 5 Dimension, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase 3
